Document:

EX-10.1(b)

 Exhibit 10.1(b) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 AMENDMENT NUMBER ONE TO LICENSE AGREEMENT 

This Amendment Number One to License Agreement (“Amendment No. 1”) is made by and between
(a) Gritstone Oncology, Inc., a Delaware corporation having a place of business at 5858 Horton Street, Suite 210, Emeryville, California 94608, U.S.A. (“Gritstone”), on the one hand, and (b) Protiva Biotherapeutics Inc., a
British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”), and Arbutus Biopharma Corporation, a British
Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“ABUS” and together with Protiva, “Arbutus”), on the
other hand. Gritstone, Protiva, and ABUS may each be referred to herein as a “Party” and collectively as the “Parties.” 

WHEREAS, the Parties entered into the License Agreement, effective on October 16, 2017, (the
“Agreement”); and 
 WHEREAS, the Parties desire to amend certain terms of the
Agreement in accordance with this Amendment No. 1, and this Amendment No. 1 shall be effective as of July 20, 2018 (the “Amendment No. 1 Effective Date”). 

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged by the Parties, the Parties, intending to be legally bound, agree as follows: 
  

	1.	 All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in
the Agreement. 

  

	2.	 The definition of “Product” shall be deleted and replaced in its entirety with the following
definition: 

 ‘“Product” means a product containing [***] RNA
that encodes [***] TSNA and that is formulated in an Arbutus LNP; provided that such RNA is part of a Self-Replicating RNA System and is not a non-replicating messenger RNA
(“mRNA”).’ 
  

	3.	 In the event of any discrepancies or conflicting terms between this Amendment No. 1 and the Agreement, the
terms of this Amendment No. 1 shall control. 

  

	4.	 The Agreement and this Amendment No. 1 represent the complete and entire understanding between the Parties
regarding the subject matter hereof and supersedes all prior negotiations, representations or agreements, either written or oral, regarding this subject matter. 

 

	5.	 This Amendment No. 1 shall be governed and interpreted in accordance with the substantive laws of the
State of New York, excluding its conflicts of laws principles. 

  
 1 

	6.	 Arbutus hereby represents, warrants, and covenants to Gritstone that: (a) as of the Amendment No. 1
Effective Date, it is entitled to grant the rights and licenses granted to Gritstone under the Agreement as amended by this Amendment No. 1, and is not currently bound by any agreement with any Third Party, or by any outstanding order,
judgment, or decree of any court or administrative agency, that restricts it in any way from granting to Gritstone the rights and licenses as set forth in the Agreement as amended by this Amendment No. 1; and (b) neither Arbutus nor any of
its Affiliates has assigned, transferred, conveyed or otherwise encumbered, nor during the Term shall assign, transfer, license, convey or otherwise encumber, its right, title and interest in the Arbutus Patents, Confidential Information and other
Licensed Intellectual Property either owned by or exclusively licensed to Arbutus as of the Effective Date in a manner that conflicts with any rights granted to Gritstone under the Agreement as amended by this Amendment No. 1.

  

	7.	 This Amendment No. 1 may be executed in counterparts, each of which shall be deemed an original and,
together, one and the same instrument. A facsimile, PDF or any other copy of this Amendment No. 1 signed by a Party is binding upon the signing Party to the same extent as the original of the signed Amendment No. 1, and may be delivered
electronically. 

  

	8.	 Except for the matters set forth in this Amendment No. 1, all other terms of the Agreement shall remain
unchanged and in full force and effect. 

 [Signature Page Follows] 

 

  
 2 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. 
 Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, authorized representatives of Gritstone, ABUS and Protiva have executed and delivered this
Amendment No. 1 effective as of the Amendment No. 1 Effective Date. 
  

			
	GRITSTONE ONCOLOGY, INC.
		
	By:	 	/s/ Andrew R. Allen
	Name:	 	Andrew R. Allen
	Title:	 	President and CEO
	
	PROTIVA BIOTHERAPEUTICS INC.
		
	By:	 	/s/ Mark J Murray
	Name:	 	Mark J Murray
	Title:	 	President and CEO
		
	By:	 	 
	Name:	 	
	Title:	 	
	
	ARBUTUS BIOPHARMA CORPORATION
		
	By:	 	/s/ Mark J Murray
	Name:	 	Mark J Murray
	Title:	 	President and CEO
		
	By:	 	 
	Name:	 	
	Title:	 	

  

  
 3 

 [***] Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. 
 Confidential treatment has been requested with respect to the omitted portions.EX-10.2

 Exhibit 10.2 
  

GRITSTONE ONCOLOGY, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

June 29, 2018 

 TABLE OF CONTENTS 

 

									
	 	 	 	 	 	  	Page	 
	 1.
	 	 Definitions
	  	 	1	 
			
	 2.
	 	 Registration Rights
	  	 	4	 
		 	 2.1
	 	 Demand Registration
	  	 	4	 
		 	 2.2
	 	 Company Registration
	  	 	6	 
		 	 2.3
	 	 Underwriting Requirements
	  	 	6	 
		 	 2.4
	 	 Obligations of the Company
	  	 	8	 
		 	 2.5
	 	 Furnish Information
	  	 	9	 
		 	 2.6
	 	 Expenses of Registration
	  	 	9	 
		 	 2.7
	 	 Delay of Registration
	  	 	10	 
		 	 2.8
	 	 Indemnification
	  	 	10	 
		 	 2.9
	 	 Reports Under Exchange Act
	  	 	12	 
		 	 2.10
	 	 Limitations on Subsequent Registration Rights
	  	 	12	 
		 	 2.11
	 	 “Market Stand-off” Agreement
	  	 	13	 
		 	 2.12
	 	 Restrictions on Transfer
	  	 	13	 
		 	 2.13
	 	 Termination of Registration Rights
	  	 	15	 
			
	 3.
	 	 Information and Observer Rights
	  	 	15	 
		 	 3.1
	 	 Delivery of Financial Statements
	  	 	15	 
		 	 3.2
	 	 Inspection
	  	 	16	 
		 	 3.3
	 	 Termination of Information Rights
	  	 	17	 
		 	 3.4
	 	 Confidentiality
	  	 	17	 
			
	 4.
	 	 Rights to Future Stock Issuances
	  	 	17	 
		 	 4.1
	 	 Right of First Offer
	  	 	17	 
		 	 4.2
	 	 Termination
	  	 	18	 
			
	 5.
	 	 Additional Covenants
	  	 	19	 
		 	 5.1
	 	 Insurance
	  	 	19	 
		 	 5.2
	 	 Employee Agreements
	  	 	19	 
		 	 5.3
	 	 Employee Stock
	  	 	19	 
		 	 5.4
	 	 Qualified Small Business Stock
	  	 	19	 
		 	 5.5
	 	 Successor Indemnification
	  	 	20	 
		 	 5.5
	 	 Director Expense Reimbursement.
	  	 	20	 
		 	 5.6
	 	 FCPA.
	  	 	20	 
		 	 5.7
	 	 Termination of Covenants
	  	 	20	 
			
	 6.
	 	 Miscellaneous
	  	 	21	 
		 	 6.1
	 	 Successors and Assigns
	  	 	21	 
		 	 6.2
	 	 Governing Law
	  	 	21	 
		 	 6.3
	 	 Counterparts
	  	 	21	 
		 	 6.4
	 	 Titles and Subtitles
	  	 	21	 
		 	 6.5
	 	 Notices
	  	 	21	 

  
 i 

									
	 	 	 	 	 	  	Page	 
		 	 6.6
	 	 Amendments and Waivers
	  	 	22	 
		 	 6.7
	 	 Severability
	  	 	22	 
		 	 6.8
	 	 Aggregation of Stock
	  	 	23	 
		 	 6.9
	 	 Additional Investors
	  	 	23	 
		 	 6.10
	 	 Entire Agreement
	  	 	23	 
		 	 6.11
	 	 Dispute Resolution
	  	 	23	 
		 	 6.12
	 	 Delays or Omissions
	  	 	24	 
		 	 6.13
	 	 Acknowledgment
	  	 	24	 

  

	Schedule A	-    Schedule of Investors 

  
 ii 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 29, 2018, by and among
Gritstone Oncology, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional
Purchaser (as defined in the Purchase Agreement (as defined below)) that becomes a party to this Agreement in accordance with Section 6.9 hereof. 

RECITALS 
 WHEREAS, the
Company and certain of the Investors (the “Existing Investors”) are parties to that certain Investors’ Rights Agreement, dated September 5, 2017 (the “Prior Agreement”). 

WHEREAS, pursuant to Section 6.6 of the Prior Agreement and subject to certain specified exceptions, any term of the Prior Agreement may
be amended and the observance of any term of the Prior Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) with the written consent of the Company and the holders of at least a majority
of the Registrable Securities (as defined in the Prior Agreement) then outstanding (the “Requisite Existing Investors”). 

WHEREAS, the Company and certain of the Investors (the “Participating Investors”) are parties to the Series C Preferred Stock
Purchase Agreement of even date herewith (as may be amended from time to time, the “Purchase Agreement”). 
 WHEREAS, in
order to induce the Company to enter into the Purchase Agreement and to induce the Participating Investors to invest funds in the Company pursuant to the Purchase Agreement, the Company and the undersigned Existing Investors, constituting the
Requisite Existing Investors, desire to amend and restate and supersede the Prior Agreement in its entirety as set forth herein and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior
Agreement. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company and the undersigned Existing Investors, constituting the Requisite Existing Investors, hereby agree that the Prior Agreement shall be amended and restated and superseded in its
entirety by this Agreement, and the parties to this Agreement further agree as follows: 
 1.    Definitions.
For purposes of this Agreement: 
 1.1    “Affiliate” means, with respect to any specified Person,
any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund
now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person. 

 1.2    “Board of Directors” means the board of directors of
the Company. 
 1.3    “Common Stock” means shares of the Company’s common stock, par value
$0.0001 per share. 
 1.4    “Damages” means any loss, damage, claim or liability (joint or several)
to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any
untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its
agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.5    “Derivative Securities” means any securities or rights convertible into, or exercisable or
exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

1.6    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. 
 1.7    “Excluded Registration” means (i) a registration
relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that
does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is
Common Stock issuable upon conversion of debt securities that are also being registered. 
 1.8    “Form
S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.9    “Form S-3” means such form under the Securities
Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.10    “GAAP” means generally accepted accounting principles in the United States. 

  
 2 

 1.11    “Holder” means any holder of Registrable Securities
who is a party to this Agreement. 
 1.12    “Immediate Family Member” means a child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, domestic partner, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, or
sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.13    “Initiating Holders” means, collectively, Holders who properly initiate a registration request
under this Agreement. 
 1.14    “IPO” means the Company’s first underwritten public offering of
its Common Stock under the Securities Act. 
 1.15     “Major Investor” means any Investor that,
individually or together with such Investor’s Affiliates, holds at least 2,500,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the
date hereof). 
 1.16    “New Securities” means, collectively, equity securities of the Company,
whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, and securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity
securities. 
 1.17    “Person” means any individual, corporation, partnership, trust, limited
liability company, association or other entity. 
 1.18    “Preferred Directors” means, collectively,
the Series A Directors (as defined in the Restated Certificate) and the Series B Director (as defined in the Restated Certificate). 

1.19    “Preferred Stock” means, collectively, shares of the Company’s Series A Preferred Stock,
Series B Preferred Stock and Series C Preferred Stock. 
 1.20    “Registrable Securities” means
(i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any
other securities of the Company acquired by the Investors after the date hereof and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a
dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which
the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 and Section 6.6 (with regard to consents to amendment and waiver) any shares for
which registration rights have terminated pursuant to Section 2.13 of this Agreement. 

1.21    “Registrable Securities then outstanding” means the number of shares determined by adding the
number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable
Securities. 

  
 3 

 1.22    “Restated Certificate” means the Company’s
Amended and Restated Certificate of Incorporation, as may be amended from time to time. 
 1.23    “Restricted
Securities” means the securities of the Company required to be notated with the legend set forth in Section 2.12(b) hereof. 

1.24    “SEC” means the Securities and Exchange Commission. 

1.25    “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.26    “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.27    “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 1.28    “Selling Expenses” means all underwriting discounts, selling
commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as
provided in Section 2.6. 
 1.29    “Series A Preferred Stock” means shares
of the Company’s Series A Preferred Stock, par value $0.0001 per share. 
 1.30    “Series B Preferred
Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001 per share. 

1.31    “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par
value $0.0001 per share. 
 2.    Registration Rights. The Company covenants and agrees as follows: 

2.1    Demand Registration. 

(a)    Form S-1 Demand. If at any time after the earlier of (i) four
(4) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least 30% of the Registrable Securities
then outstanding that the Company file a Form S-1 registration statement with respect to at least thirty percent (30%) of the Registrable Securities then outstanding (or a lesser percent if the
anticipated aggregate offering price, net of Selling Expenses, would exceed $10.0 million), then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to
all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days 

  
 4 

 
after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable
Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company
within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

(b)    Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form
S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $10.0 million, then the
Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days
after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration
by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

(c)    Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant
to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders
for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant
acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or
(iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or
effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than
once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such ninety (90) day period other than an Excluded
Registration. 
 (d)    The Company shall not be obligated to effect, or to take any action to effect, any registration
pursuant to Section 2.1(a)(i) during the period that is one hundred twenty (120) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty
(180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective;
(ii) after the Company has effected two registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company 

  
 5 

 
shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i) during the period that is thirty (30) days before the
Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith
commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two (2) registrations pursuant to Section 2.1(b) within the twelve (12) month period immediately
preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the
SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in
which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d). 

2.2    Company Registration. If the Company proposes to register (including, for this purpose, a registration
effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall,
at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of
Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it
under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn
registration shall be borne by the Company in accordance with Section 2.6. 
 2.3    Underwriting
Requirements. 
 (a)    If, pursuant to Section 2.1, the Initiating Holders intend
to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such
information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s
Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders
proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for
such underwriting. Notwithstanding any other provision of this Section 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to
be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be
allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as 

  
 6 

 
nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided,
however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of
shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

(b)    In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to
Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and
its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in
proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance
with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable
Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be
reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and
no other stockholder’s securities are included in such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company,
or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts
for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities
owned by all Persons included in such “selling Holder,” as defined in this sentence. 

  
 7 

 2.4    Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its
commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period
of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be
extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any
registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day
period shall be extended for up to one hundred eighty (180) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b)    prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus
used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c)    furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as
required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d)    use its commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e)    in the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f)    use its commercially
reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities
issued by the Company are then listed; 
 (g)    provide a transfer agent and registrar for all Registrable Securities
registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h)    promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any
disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the 

  
 8 

 
selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent
accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to
conduct appropriate due diligence in connection therewith; 
 (i)    notify each selling Holder, promptly after the
Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j)    after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after
any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under
Rule 10b5-1 of the Exchange Act. 
 2.5    Furnish Information. It shall
be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such
information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6    Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with
registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the
reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be
required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities
to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable
Securities agree to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material
adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such material adverse change, then the
Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this
Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

  
 9 

 2.7    Delay of Registration. No Holder shall have any right to
obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 2. 
 2.8    Indemnification. If any Registrable Securities are included in a
registration statement under this Section 2: 
 (a)    To the extent permitted by law, the
Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities
Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling
Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided,
however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company,
which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished
by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

(b)    To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless
the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any
underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such
Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such
selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses
are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections
2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

  
 10 

 (c)    Promptly after receipt by an indemnified party under this
Section 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the
extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however,
that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such
action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this
Section 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that
it may have to any indemnified party otherwise than under this Section 2.8. 
 (d)    To
provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this
Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such
indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of
any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may
be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted
in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things,
whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent,
knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering
price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be
entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when
combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of
willful misconduct or fraud by such Holder. 

  
 11 

 (e)    Notwithstanding the foregoing, to the extent that the provisions on
indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f)    Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public
offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and
otherwise shall survive the termination of this Agreement. 
 2.9    Reports Under Exchange Act. With a view to
making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 
 (a)    make and keep available adequate current public
information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b)    use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents
required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to
the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the
IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any
such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies
to use such form). 
 2.10    Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that
(i) would provide to such holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to
include in the registration and offering all shares of Registrable Securities that they wish to so include; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or
prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Section 6.9. 

  
 12 

 2.11    “Market
Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus
relating to the registration by the Company of shares of its Common Stock or any other equity securities under the Securities Act for its IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one
hundred eighty (180) days), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of,
directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock (whether such shares or any such securities are then owned by the Holder or are thereafter
acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above
is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an
underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in
writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers, directors and holders of one percent (1%)
or more of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to substantially the same restrictions. The underwriters in connection with such registration
are intended third-party beneficiaries of this Section 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each
Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further
effect thereto. Subject to customary shareholding thresholds and other customary exceptions, any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all
Holders subject to such agreements, based on the number of shares subject to such agreements. 

2.12    Restrictions on Transfer. 

(a)    The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure
compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement. 

  
 13 

 (b)    Each certificate, instrument, or book entry representing (i) the
Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or
similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c)    The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with
the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction,
the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail
and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to
the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such
Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that
the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted
Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in
any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this
Section 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate
restrictive legend set forth in Section 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such
legend is not required in order to establish compliance with any provisions of the Securities Act. 

  
 14 

 2.13    Termination of Registration Rights. The right of any Holder
to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a)    the closing of a Deemed Liquidation Event described in Article Fourth, Part B, Section 2.3.1(a) of the
Restated Certificate; 
 (b)    with respect to a Holder, such time after the IPO when such Holder (X) can sell all
shares held by it (together with any Affiliate of the Holder with whom such Holder must aggregate its sales under Rule 144) in compliance with Rule 144(b)(1)(i) or (Y) holds one percent (1%) or less of the Company’s outstanding Common
Stock and all Registrable Securities of the Company issuable or issued upon conversion of the Shares held by and issuable to such Holder (together with any Affiliate of the Holder with whom such Holder must aggregate its sales under Rule 144) may be
sold pursuant to Rule 144 without limitation during a three-month period without registration; and 
 (c)    the third
anniversary of the IPO. 
 3.    Information and Observer Rights. 

3.1    Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that
the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company (it being understood, acknowledged and agreed that for all purposes under this Agreement (including Sections 3.2 and 3.4), none of the
following entities shall be deemed to be a “competitor” of the Company: (i) any financial investment firm or collective investment vehicle solely by virtue of its ownership (and/or its Affiliates’ ownership) of an equity interest
in any competitor held solely for investment purposes, or (ii) GV 2017, L.P. or any of its affiliated funds, solely as a result of any affiliation between such fund and Alphabet Inc. (including any Affiliate of Alphabet Inc.)): 

(a)    as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal
year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial
statements audited and certified by independent public accountants selected by the Company; 
 (b)    as soon as
practicable, but in any event within forty-five (45) days after the end of each fiscal quarter of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter,
and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments;
and (ii) not contain all notes thereto that may be required in accordance with GAAP); 
 (c)    as soon as
practicable, but in any event within thirty (30) days after the end of each month, unaudited statements of income and cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP
(except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

  
 15 

 (d)    as soon as practicable, but in any event within (30) days after
the end of each fiscal year, or reasonably promptly following a written request by a Major Investor, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of
capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the
number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company; 

(e)    as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and
business plan for the next fiscal year (collectively, the “Budget”), prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other
budgets or revised budgets prepared by the Company; 
 (f)    such other information relating to the financial
condition, capitalization, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this
Section 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or highly confidential proprietary information (unless covered by an enforceable confidentiality
agreement, in a form acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information
set forth in this Section 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it must do so to comply with the
SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively
employing its commercially reasonable efforts to cause such registration statement to become effective. 

3.2    Inspection. The Company shall permit each Major Investor (provided that the Board of Directors has
not reasonably determined that such Major Investor is a competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s
affairs, finances, and accounts with its officers, during normal business hours of the Company as 

  
 16 

 
may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any
information that it reasonably and in good faith considers to be a trade secret or highly confidential proprietary information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which
would adversely affect the attorney-client privilege between the Company and its counsel. 
 3.3    Termination of
Information Rights. The covenants set forth in Section 3.1 and Section 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO,
(ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event described in Article Fourth, Part B, Section 2.3.1(a) of
the Restated Certificate, whichever event occurs first. 
 3.4    Confidentiality. Each Investor agrees that
such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement
(including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this
Section 3.4 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the
Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants,
consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such
prospective purchaser agrees to be bound by the provisions of this Section 3.4 and is not a competitor of the Company; (iii) to any existing Affiliate, partner, member, stockholder, or wholly owned subsidiary of
such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise
be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

4.    Rights to Future Stock Issuances. 

4.1    Right of First Offer. Subject to the terms and conditions of this Section 4.1 and
applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby
granted to it, in such proportions as it deems appropriate, among itself and its Affiliates. 
 (a)    The Company
shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if
any, upon which it proposes to offer such New Securities. 

  
 17 

 (b)    By notification to the Company within twenty (20) days after the
Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held
by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to
the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall
promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day
period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New
Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion
and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as
applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this
Section 4.1(b) shall occur within the later of one hundred and twenty (120) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c). 

(c)    If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in
Section 4.1(b), the Company may, during the one hundred twenty (120) day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed
portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New
Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first
reoffered to the Major Investors in accordance with this Section 4.1. 
 (d)    The right of
first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Restated Certificate); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares
of Series C Preferred Stock to pursuant to the Purchase Agreement. 
 4.2    Termination. The covenants set
forth in Section 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) upon a Deemed Liquidation Event described in Article Fourth, Part B,
Section 2.3.1(a) of the Restated Certificate, whichever event occurs first. 

  
 18 

 5.    Additional Covenants. 

5.1    Insurance. The Company shall maintain, from financially sound and reputable insurers, Directors and
Officers liability insurance and term “key-person” insurance on Andrew Allen, each in an amount and on terms and conditions satisfactory to the Board of Directors, until such time as the Board of
Directors determines that such insurance should be discontinued. The key-person policy shall name the Company as loss payee, and neither policy shall be cancelable by the Company without prior approval by the
Board of Directors, including a majority of the then-serving Preferred Directors. 
 5.2    Employee Agreements.
The Company will cause each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement.
In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of the
Board of Directors. 
 5.3    Employee Stock. Unless otherwise approved by the Board of Directors, all
future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as
applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares
vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in
Section 2.11. In addition, unless otherwise approved by the Board of Directors, the Company shall retain a “right of first refusal” on employee transfers until the IPO and shall have the right to repurchase unvested
shares at cost upon termination of employment of a holder of restricted stock. 
 5.4    Qualified Small Business
Stock. The Company shall use commercially reasonable efforts to cause the shares of Series A Preferred Stock issued pursuant to that certain Series A Preferred Stock Purchase Agreement, dated September 18, 2015 (the “Series A
Purchase Agreement”) in the First Tranche Closing (as defined in the Series A Purchase Agreement), as well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the Internal Revenue Code (the
“Code”), to constitute “qualified small business stock” as defined in Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of Directors determines,
in its good-faith business judgment, that such qualification is inconsistent with the best interests of the Company. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may be
required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, within twenty (20) business days after any Investor’s written request therefor, the Company shall, at its option, either
(i) deliver to such Investor a written statement indicating whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code or
(ii) deliver to such Investor such factual information in the Company’s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s interest in the Company constitutes
“qualified small business stock” as defined in Section 1202(c) of the Code. 

  
 19 

 5.5    Successor Indemnification. If the Company or any of its
successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the
successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the
Company’s Bylaws, its Restated Certificate, or elsewhere, as the case may be. 
 5.5 Director Expense Reimbursement. The
Company shall promptly reimburse each non-employee director of the Company for all of his or her reasonable and actual
out-of-pocket expenses (including travel expenses) incurred in attending each meeting of the Board of Directors or a committee thereof or otherwise incurred in the
course of performing his or her duties as a director of the Company, subject at all times to the Company’s standard travel and reimbursement policies. 

5.6    FCPA. The Company shall not (and shall not permit any of its subsidiaries or affiliates or any of its or
their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third party,
including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery
Act, or any other applicable anti-bribery or anti-corruption law. The Company shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company,
its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or
anti-corruption law. The Company shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure
compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive information and/or certifications concerning its compliance with applicable
anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase Agreement). The Company shall, and shall cause any direct or indirect subsidiary or entity
controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all
material respects with all applicable laws. 
 5.7 Termination of Covenants. The covenants set forth in this Section 5, except
for Section 5.5, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) upon a Deemed Liquidation Event described in Article Fourth, Part B,
Section 2.3.1(a) of the Restated Certificate, whichever event occurs first. 

  
 20 

 6.    Miscellaneous. 

6.1    Successors and Assigns. The rights under this Agreement may be assigned (but only with all related
obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s
Immediate Family Members; or (iii) after such transfer, holds at least 1,000,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided,
however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being
transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of
determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a
trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify
individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this
Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party
other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2    Governing Law. This Agreement shall be governed by the internal law of the State of California. 

6.3    Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  

6.4    Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not
to be considered in construing or interpreting this Agreement. 
 6.5    Notices. All notices and other
communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by
electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight 

  
 21 

 
courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at
their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as
subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy shall also be sent to (which shall not constitute notice): Latham & Watkins LLP, 140
Scott Drive, Menlo Park, California 94025 Attn: Alan C. Mendelson, Esq. and Brian J. Cuneo, Esq. (facsimile: (650) 463-2600; email: alan.mendelson@lw.com and brian.cuneo@lw.com). 

6.6    Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least a majority of the shares constituting Registrable Securities
then outstanding; provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in
violation of Section 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.
Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or
waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if
such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction); provided that in the event of a waiver of Section 4 by the Major
Investors with respect to the issuance of New Securities, to the extent that any Major Investor nonetheless purchases New Securities in the transaction that gave rise to such waiver (any such Major Investor, a “Participating
Investor”), then each other Major Investor shall be permitted to purchase up to the same percentage (not to exceed 100%) of its pro rata share of New Securities issued in the transaction as the percentage of the pro rata share of the New
Securities so purchased by the Participating Investor purchasing the largest portion of such Participating Investor’s pro rata share in the transaction); provided further that the foregoing right may be waived individually by any Major
Investor. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected
in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in
any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7    Severability. In case any one or more of the provisions contained in this Agreement is for any reason held
to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so
that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

  
 22 

 6.8    Aggregation of Stock. All shares of Registrable Securities
held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem
appropriate. 
 6.9    Additional Investors. Notwithstanding anything to the contrary contained herein, if the
Company issues additional shares of Series C Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series C Preferred Stock may become a party to this Agreement by executing
and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement
by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10    Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and
entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness
of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded in its entirety by this Agreement, and shall be of no further force or effect. 

6.11    Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction
of the state courts of California and to the jurisdiction of the United States District Court for the District of Northern District for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree
not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of California or the United States District Court for the District of Northern California, and (c) hereby waive,
and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from
attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. 
 WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY
COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY
DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY
KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

  
 23 

 The prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary
disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the U.S. District Court for the District of Northern
California or any court of the State of California having subject matter jurisdiction. 
 6.12    Delays or
Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such
nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed
a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.13    Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital
investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this
Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

[Remainder of Page Intentionally Left Blank] 

  
 24 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	THE COMPANY:
	
	GRITSTONE ONCOLOGY, INC.
		
	By:	 	/s/ Andrew Allen
	Name: Andrew Allen
	Title: President and Chief Executive Officer

  

SIGNATURE PAGE TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT OF 
 GRITSTONE ONCOLOGY, INC. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTOR:
	
	ALTITUDE LIFE SCIENCE VENTURES
FUND II, L.P.
		
	By:	 	/s/ David Maki
	Name: David Maki
	Title: Managing Member
	
	ALTITUDE LIFE SCIENCE VENTURES SIDE FUND II, L.P.
		
	By:	 	/s/ David Maki
	Name: David Maki
	Title: Managing Member

  

			
	Address:	 	1014 Market Street, Suite 200
		 	Kirkland, WA 98033

  

SIGNATURE PAGE TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT OF 
 GRITSTONE ONCOLOGY, INC. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTOR:
	
	Clarus Lifesciences III, L.P.
		
	By:	 	 Clarus Ventures III GP, LP,
 it’s General
Partner

		
	By:	 	 Clarus Ventures III, LLC,
 it’s General
Partner

		
	By:	 	/s/ Nick Simon
	Name: Nick Simon
	Title: Managing Director

  

SIGNATURE PAGE TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT OF 
 GRITSTONE ONCOLOGY, INC. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTORS:
	
	The Column Group II, LP
	
	 By: The Column Group II GP, LP
 Its:
General Partner

	
	 By: The Column Group, LLC
 Its:
General Partner

		
	By:	 	/s/ Peter Svennilson
	Name: Peter Svennilson
	Title: Managing Partner

  

SIGNATURE PAGE TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT OF 
 GRITSTONE ONCOLOGY, INC. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTOR:
	
	Frazier Healthcare VII, L.P.
	
	By: FHM VII, LP, its general partner
	By: FHM VII, LLC, its general partner
		
	By:	 	/s/ James Topper
	James Topper, Managing General Partner
	
	Frazier Healthcare VII-A, L.P.
	
	By: FHM VII, LP, its general partner
	By: FHM VII, LLC, its general partner
		
	By:	 	/s/ James Topper
	James Topper, Managing General Partner

  

SIGNATURE PAGE TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT OF 
 GRITSTONE ONCOLOGY, INC. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTOR:
	
	LAV Auspicium Limited
		
	By:	 	/s/ Judith Li
	Name: Judith Li
	Title: Authorized Signatory
	
	LAV Aria Limited
		
	By:	 	/s/ Judith Li
	Name: Judith Li
	Title: Authorized Signatory
	
	LAV Zenith Limited
		
	By:	 	/s/ Judith Li
	Name: Judith Li
	Title: Authorized Signatory

  

SIGNATURE PAGE TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT OF 
 GRITSTONE ONCOLOGY, INC. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTOR:
	
	Marshfield Advisers, LLC
		
	By:	 	/s/ Scott Carman
	Name: Scott Carman
	Title: Portfolio Manager

  

SIGNATURE PAGE TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT OF 
 GRITSTONE ONCOLOGY, INC. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTOR:
	
	PFM Healthcare Master Fund, L.P.
		
	By:	 	 Partner Fund Management, L.P.
 its investment
adviser

		
	By:	 	/s/ Yuan DuBord
	Name: Yuan DuBord
	Title: CFO
	
	PFM Healthcare Principals Fund, L.P.
		
	By:	 	 Partner Investment Management, L.P.
 its
investment adviser

		
	By:	 	/s/ Yuan DuBord
	Name: Yuan DuBord
	Title: CFO
	
	PFM Healthcare Emerging Growth Master
Fund, L.P.
		
	By:	 	 Partner Fund Management, L.P.
 its investment
adviser

		
	By:	 	/s/ Yuan DuBord
	Name: Yuan DuBord
	Title: CFO

  

SIGNATURE PAGE TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT OF 
 GRITSTONE ONCOLOGY, INC. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTOR:
	
	Redmile Capital Fund, LP
		
	By:	 	/s/ Jeremy Green
	Name: Jeremy Green
	Title: Managing Member of the General Partner and the Investment Manager
	
	Redmile Capital Offshore Fund, Ltd.
		
	By:	 	/s/ Jeremy Green
	Name: Jeremy Green
	Title: Managing Member of the Investment Manager
	
	Redmile Capital Offshore Fund II, Ltd.
		
	By:	 	/s/ Jeremy Green
	Name: Jeremy Green
	Title: Managing Member of the Investment Manager
	
	Redmile Strategic Master Fund LP
		
	By:	 	/s/ Jeremy Green
	Name: Jeremy Green
	Title: Managing Member of the General Partner and Investment Manager
	
	Redmile Biopharma Investments I, L.P.
		
	By:	 	/s/ Jeremy Green
	Name: Jeremy Green
	Title: Managing Member of the General Partner and the Management Company
	
	 Address:
 One Letterman Drive,
Building D, Suite D3-300
 San Francisco, CA 94129

Telephone: 415-489-9980

Email: #####################
 Attn: Josh Garcia

  

SIGNATURE PAGE TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT OF 
 GRITSTONE ONCOLOGY, INC. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	INVESTOR:
	
	 Versant Venture Capital V, L.P.

Versant Affiliates Fund V, L.P.
 Versant Ophthalmic
Affiliates Fund I, L.P.
 By: Versant Ventures V, LLC

Its: General Partner

		
	By:	 	/s/ Thomas Woiwode
	Name: Thomas Woiwode
	Title: Managing Director
	
	 Versant Venture Capital V (Canada) LP

By: Versant Ventures V (Canada), L.P.
 By: Versant
Ventures V GP-GP (Canada), Inc.
 Its: General Partner

		
	By:	 	/s/ Thomas Woiwode
	Name: Thomas Woiwode
	Title: Director

  

SIGNATURE PAGE TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT OF 
 GRITSTONE ONCOLOGY, INC. 

 SCHEDULE A 

Investors 
 PFM HEALTHCARE MASTER FUND,
L.P. 
 PFM HEALTHCARE PRINCIPALS FUND, L.P. 
 PFM
HEALTHCARE EMERGING GROWTH MASTER FUND, L.P. 
 4 Embarcadero Center, Suite 3500 

San Francisco, CA 94111 
 Attn: Darin Sadow 

Email: ############### 
 MARSHFIELD ADVISERS, LLC 

60 East South Temple Street, Suite 400 
 Salt Lake City, UT 84111

 Attention: Scott Carman  
 TRINITAS CAPITAL G,
L.P. 
 401, 4/F Building 2, No. 39, Dongzhimenwai Street, 

Dongcheng District, Beijing, China 
 Attn: Bing Han 

Email: ######################### 
 LAV Auspicium Limited

 28 Hennessy Road 6F 
 Admiralty, Hong Kong 

Attn: Judith Li 
 Email: ################# 

LAV Aria Limited 
 28 Hennessy Road 6F 

Admiralty, Hong Kong 
 Attn: Judith Li 

Email: ################# 
 LAV Zenith Limited 

28 Hennessy Road 6F 
 Admiralty, Hong Kong 

Attn: Judith Li 
 Email: ################# 

GV 2017, L.P. 
 1600 Amphitheatre Parkway 

Mountain View, CA 94043 
 Email: ############ 

 Alexandria Ventures Investments, LLC 

385 E. Colorado Blvd., Suite 299 
 Pasadena, CA 91101 

Attn: Christopher Otey 
 Email: ##########; ##################

 Versant Venture Capital V, L.P. 
 Versant
Affiliates Fund V, L.P. 
 Versant Ophthalmic Affiliates Fund I, L.P. 

Versant Venture Capital V (Canada) LP 
 One Sansome Street,
Suite 3630 
 San Francisco, CA 94104 
 Fax: (415) 801-8101 
 Attn: Tom Woiwode 

Email: ##################### 
 The Column Group II, LP

 1700 Owens Street, Suite 500 
 San Francisco, CA 94158

 Fax: (415) 255-2048 

Attn: Peter Svennilson 
 Email: ################## 

Clarus Lifesciences III, L.P. 
 601 Gateway Boulevard,
Suite 1270 
 South San Francisco, CA 94080 
 Phone: (650) 238-5000 
 Attn: Nick Simon 

Email: ##################### 
 Frazier Healthcare VII, L.P.

 Frazier Healthcare VII-A, L.P. 

610 Union Street, Suite 3200 
 Seattle, WA 98101 

Fax: ### ###-#### 
 Attn: James Topper 

Email: ##################### 
 Redmile Capital Fund, LP

 Redmile Capital Offshore Fund, Ltd. 
 Redmile
Capital Offshore Fund II, Ltd. 
 Redmile Strategic Master Fund, Ltd. 

Redmile Biopharma Investments I, L.P. 
 One Letterman
Drive, Building D, Suite D3-300 
 The Presidio of San Francisco 

San Francisco, CA 94129 
 Phone: (415) 489-9980 
 Attn: Josh Garcia 

 Casdin Partners Master Fund LP 

Attn: Matt Ehrhart 
 1350 Avenue of the Americas, Suite 1140 

New York, NY 10019 
 Phone: (212)
897-5430 
 Email: ################# 

Transformational Healthcare Opportunity (LT), LLC 
 Attn:
Darren F. Hite 
 2384 Union Street 
 San Francisco, CA 94123

 Email: ##################### 
 Patrick J. Mahaffy

 c/o Clovis Oncology 
 2525 28th Street, Suite 100 
 Boulder, CO 80301 

Phone: ### ###-#### 
 Email: ######################### 

Atwood-Edminster Trust, dtd 4/2/00 
 Attn: Brian Atwood

 #### ######### #### 
 ######### ## ##### 

Phone: ### ###-#### 
 Email: ################# 

Aberdare Management Company, LLC 
 235 Montgomery Street,
Suite 1230 
 San Francisco, CA 94104 
 Phone: 415-392-7442 
 Attn: Paul Klingenstein 

Email: ##################### 
 Copy to: ############### 

Robert Nelsen 
 ##### ##### ###### 

########## ## ##### 
 Phone: ### ###-#### 

Email: ############### 

 Preston Family Trust 

Attn: Heather Preston 
 ## ######## ##### 

####### ## ##### 
 Phone: ### ###-#### 

Email: ############# 
 Jonathan MacQuitty 

### ######## #### 
 ######## ## ##### 

Email: ################## 
 Phone: ### ###-#### 

Fred E. Cohen and Carolyn B. Klebanoff Trust 
 ###
########## ##### 
 ########## ## ##### 
 Phone: ### ###-####

 Email: ############## 
 Bonderman Family Limited
Partnership 
 Attn: Sherri Conn 
 301 Commerce Street,
Suite 3300 
 Fort Worth, TX 76102 
 Phone: ### ###-#### 

Email: ########################## 
 Keith Manchester 

### #### ### ### ##### 
 ####### ## ##### 

Phone: ### ###-#### 
 Email: ##################### 

Altitude Life Science Ventures Fund II, L.P. 
 Altitude
Life Science Ventures Side Fund II, L.P. 
 1014 Market St, Suite 200 

Kirkland, WA 98033 
 Attn: David Maki 

Email: ################## 
 Tel: ### ###-#### 

Roger A. Allen 
 ## ####### #### 

###### ##### 
 ##### #### #### ### 

###### ##### 
 Phone: ##-#-###-###-### 

Email: ################## 

 Darshan Moroak 

#### ###### ### 
 ###### ## ##### 

Phone: ### ###-#### 
 Email: ################### 

Parminder Moroak 
 ####### ######## #### 

######### ## ##### 
 Phone: ### ###-#### 

Email: ################# 
 Opinder Moroak 

#### ####### ### 
 ###### ## ##### 

Phone: ### ###-#### 
 Email: osmoroak@yahoo.com 

Dr. Paul Jarman 
 ## ####### ###### 

####### ### #### 
 ####### ####### 

Phone: ##-#-#####-#### 
 Email: #################### 

Patrick Boggon 
 ####### ######### 

###### ######### ### ### 
 ####### ###### 

Phone: ##-#-#####-##### 
 Email: ################## 

Vladimir & Irina Yelensky 
 ## ####### #######

 ######## ## ##### 
 ### ###-#### 

################### 
 VP Company Investments 2008, LLC

 c/o Latham & Watkins LLP 
 Attn: Alfred
Harutunian 
 555 West Fifth Street – Suite 800 
 Los
Angeles, CA 90013-1021 
 Fax: (213) 891-1200 

Email: #################### 

 VP Company Investments 2016, LLC 

c/o Latham & Watkins LLP 
 Attn: Alfred Harutunian 

555 West Fifth Street – Suite 800 
 Los Angeles, CA
90013-1021 
 Fax: (213) 891-1200 

Email: ################### 
 Alan C. & Agnes B. Mendelson
Family Trust 
 ## ###### #### 
 ##### ## ##### 

Fax: ### ###-#### 
 Email: #################### 

Brian Cuneo 
 c/o Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park, CA 94025 

Fax: (650) 463-2600 

Email: #################### 
 Joshua N. Holian 

c/o Latham & Watkins LLP 
 505 Montgomery Street, 20th
Floor 
 San Francisco, CA 94111-6538 
 Fax: (415) 395-8095 
 Email: ##################### 

Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. 

750 Battery Street, Suite 400 
 San Francisco, CA 94111 

Attn: Dayton Misfeldt 
 Email: ######################### 

Dashaco Limited 

12-14 Finch Road 

Douglas, Isle of Man, IM1 2PT 
 Attn: Stephen Schuster 

Email: ################## 
 Attn: Stephen Wilson 

Email: ##################

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]